BMS-backed liq­uid biop­sy biotech Pre­cede Bio­sciences de­buts to en­hance pre­ci­sion med­i­cine ap­proach­es

Pre­cede Bio­sciences has emerged with a liq­uid biop­sy plat­form that can il­lu­mi­nate a pa­tient’s bi­o­log­i­cal state and would serve as the foun­da­tion for blood tests to help drug­mak­ers build a pic­ture of pa­tients like­ly to re­spond to treat­ments.

Many pre­ci­sion med­i­cine ef­forts have fo­cused on gene mu­ta­tions, but the Boston, MA-based com­pa­ny has a broad­er ap­proach. “There are so many oth­er con­texts that are non-mu­ta­tion­al­ly dri­ven. Where there’s a [non-mu­ta­tion­al] mol­e­c­u­lar mech­a­nism un­der­ly­ing the dis­ease… we’re fo­cused on ad­dress­ing those,” CEO Re­han Ver­jee told End­points News in an in­ter­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER